Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Semaglutide and Vascular Regeneration in People with Diabetes

EF 2022-23

Résumé
The leading causes of death in people with type-2 diabetes (T2D) are cardiovascular diseases (CVD), such as heart attack and stroke. While the exact relationship between T2D and increased CVD risk is unclear, we believe that CVD is connected to the quantity of rare stem cells in our blood responsible for repairing blood vessels, known as ‘vascular regenerative (VR) cells’. We recently developed a new technique that measures VR stem cells circulating in blood. Using this innovative tool, we discovered that people with T2D had fewer VR cells in their blood compared to people without T2D. Interestingly, the number of VR cells was increased after bariatric surgery, a procedure that drastically reduces body weight and increases the production of a beneficial gut hormone named GLP-1. Semaglutide is a newly developed drug that mimics the actions of GLP-1. In a landmark clinical trial, semaglutide has been shown to efficiently lower blood glucose, reduce body weight, and reduce the rate of heart attack and stroke in people with T2D by 26%. However, researchers do not yet understand how semaglutide reduces CVD events. We predict that in people with T2D, semaglutide treatment will increase the number of VR cells in the blood. We will enroll 100 people with T2D into a clinical trial: 50 will receive semaglutide and 50 will not. From each participant, blood samples will be collected at the beginning of study and after 6 months of treatment, and the changes in VR cells will be measured. Our study will help understand how semaglutide reduces CVD in people with T2D and support its use as a medication to prevent CVD. Understanding how semaglutide improves blood vessel repair will also help scientists develop new drugs that more efficiently prevent CVD in people with T2D and obesity.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486166
Name
Park Brady
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Semaglutide and Vascular Regeneration in People with Diabetes
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Angiogenesis; Glp-1; Glp-1 Receptor Agonists; Granulocytes; Hematopoietic Progenitor Cells; Inflammation; Macrophages; Monocytes; Semaglutide; Vascular Regeneration
Abstract
The leading causes of death in people with type-2 diabetes (T2D) are cardiovascular diseases (CVD), such as heart attack and stroke. While the exact relationship between T2D and increased CVD risk is unclear, we believe that CVD is connected to the quantity of rare stem cells in our blood responsible for repairing blood vessels, known as ‘vascular regenerative (VR) cells’. We recently developed a new technique that measures VR stem cells circulating in blood. Using this innovative tool, we discovered that people with T2D had fewer VR cells in their blood compared to people without T2D. Interestingly, the number of VR cells was increased after bariatric surgery, a procedure that drastically reduces body weight and increases the production of a beneficial gut hormone named GLP-1. Semaglutide is a newly developed drug that mimics the actions of GLP-1. In a landmark clinical trial, semaglutide has been shown to efficiently lower blood glucose, reduce body weight, and reduce the rate of heart attack and stroke in people with T2D by 26%. However, researchers do not yet understand how semaglutide reduces CVD events. We predict that in people with T2D, semaglutide treatment will increase the number of VR cells in the blood. We will enroll 100 people with T2D into a clinical trial: 50 will receive semaglutide and 50 will not. From each participant, blood samples will be collected at the beginning of study and after 6 months of treatment, and the changes in VR cells will be measured. Our study will help understand how semaglutide reduces CVD in people with T2D and support its use as a medication to prevent CVD. Understanding how semaglutide improves blood vessel repair will also help scientists develop new drugs that more efficiently prevent CVD in people with T2D and obesity.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Park, Brady
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~